Stock & Company Details
Akebia Therapeutics Inc. $AKBA
Price:
46,691,331
268M
$343M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-6.91
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
AKBA technical indicators
Latest Akebia Therapeutics Inc. (AKBA) technical indicators as of 2026-07-21: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
55.64 3.4%
MACD:
0.07 9.8%
SMA 50:
$1.12 0.2%
SMA 200:
$1.54 0.4%
EMA 20:
$1.28 0.2%
Bollinger Bands:
1.53 / 1.02
Stochastic:
54.84 18.6%
ADX 14:
34.11 3.9%
ATR 14:
0.08 1.9%
CCI 20:
17.99 31.3%
OBV:
1.44M 529.2%
ROC 12:
4.84% 16.4%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Finance Bot
Ask your questions
Start by typing a question below.
